IP Library Granted Patent US 10,576,286
Granted Patent B1
US 10,576,286 · App. 16/048,138 · Granted Mar 3, 2020

Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods

Inventor: Sangsoo Wesley Park (San Jose, CA)
Assignee: Nevro Corp.
A61N1/36175A61N1/0553A61N1/36071A61N1/36157A61N1/36171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,576,286
App. No.
16/048,138
Granted
Mar 3, 2020
Kind
B1
Abstract

Short pulse width spinal cord modulation for inhibiting pain with reduced side effects and associated systems and methods are disclosed. In particular embodiments, modulation signal has pulse widths in the range of from about 10 microseconds to about 50 microseconds may be applied to the patient's spinal cord region to address chronic pain without using paresthesia or tingling to mask or cover the patient's sensation of pain. In other embodiments, modulation in accordance with similar parameters can be applied to other spinal or peripheral locations to address other indications.

Claims (15)

1. A method for reducing or eliminating pain in a patient, without causing paresthesia in the patient, the method comprising:

programming a computer-readable medium of an implanted signal generator to:

generate a non-paresthesia-producing therapy signal, wherein at least a portion of the therapy signal is at a frequency of from 500 Hz to 1.2 kHz, with a pulse width in a pulse width range from 10 microseconds to 50 microseconds, and a current amplitude in a current amplitude range from 0.5 mA to 20 mA; and

transmit the therapy signal to the dorsal column of the patient's spinal cord via a signal delivery device implanted in the patient's epidural space and electrically coupled to the implanted signal generator.

2. The method of claim 1 , wherein the therapy signal has a duty cycle.

3. The method of claim 2 , wherein the duty cycle is 100%.

4. The method of claim 2 , wherein the duty cycle is 50-100%.

5. The method of claim 2 , wherein the frequency is applied throughout the length of an on period in the duty cycle.

6. The method of claim 2 , wherein the frequency is applied during a portion of an on period in the duty cycle.

7. The method of claim 1 , wherein the therapy signal has a current amplitude of about 2.5 mA.

8. The method of claim 1 , wherein at least a portion of the therapy signal is a square-wave signal.

9. The method of claim 1 , wherein the signal delivery device is a percutaneous lead.

10. The method of claim 1 , wherein the signal delivery device is a paddle lead.

11. The method of claim 1 , wherein the signal delivery device is an elongated lead having one or more electrodes.

12. The method of claim 1 , wherein the signal delivery device is an elongated lead having a bipole arrangement of electrodes.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: NEVRO CORP.
Reel/Frame 070743/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 1, 2023
From: NEVRO CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 065744/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2018
From: PARK, SANGSOO WESLEY
To: NEVRO CORP.
Reel/Frame 046981/0489 →
Continuity (2)
Continuation 14534769 · Nov 6, 2014
Provisional Application 61901255 · Nov 7, 2013
Cited By (6)
US 12,285,611 US 12,390,645 US 12,433,528 US 12,465,776 US 12,491,365 US 12,558,547